SCHEMBL6794084

SCHEMBL6794084

COc1cc2c(c(OC)c1OC)CCC(/C=C/C(=O)N1CCCN(C(=O)/C=C/C3=Cc4cc(OC)c(OC)c(OC)c4CC3)CC1)=C2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.55
KDM4E B2RXH2 6/20 0.55
HPGD P15428 4/20 0.55
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.43
ATM Q13315 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
MAPT P10636 2/20 0.42
STAT6 P42226 1/20 0.42
TP53 P04637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ACHE P22303 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
BCHE P06276 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785483 0.83 KMT2A (0.51) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6783071 0.82 KDM4E (0.51) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6786054 0.80 KDM4E (0.52) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL4270404 0.79 KMT2A (0.55) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6788079 0.78 KDM4E (0.52) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6784933 0.77 KDM4E (0.54) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL6793154 0.74 LMNA (0.40) ALDH1A1KDM4EKMT2AMEN1ATM
SCHEMBL5569532 0.72 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL5569531 0.72 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDKMT2AMEN1
Cinoctramide SCHEMBL2111109 0.71 ALDH1A1 (0.97) ALDH1A1KDM4EHPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828316-B2 Antiallergens KOWA CO., LTD. (JP) 2004-12-07 US disclosed
US-20020042414-A1 Diamide compound and medicine containing the same KOWA CO., LTD. (JP) 2002-04-11 US disclosed
US-6340682-B1 FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS KOWA CO., LTD. (JP) 2002-01-22 US disclosed
EP-0926138-A1 DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO. LTD. (JP) 1999-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042414-A1 Diamide compound and medicine containing the same HRH4, HRH2, HRH1 ALDH1A1 836/4885KDM4E 562/4885HPGD 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.